Isarna Therapeutics GmbH   Report issue

For profit Phase 1 Phase 3
Founded: Munich Germany (1998)
Status: Left NME R&D (2019)

Organization Overview

First Clinical Trial
2003
NCT00431561
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Isarna Therapeutics

Active Ingredients

Drugs in Phase 3 Trials (4)

carmustine (bicnu) (1 trial)

lomustine (1 trial)

temozolomide (temodar) (2 trials)

trabedersen (3 trials)

Drugs in Phase 1 Trials (1)

tgf-β2 antisense oligonucleotide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Astrocytoma (Phase 3)

Colorectal Neoplasms (Phase 1)

Glaucoma (Phase 1)

Glaucoma, Open-Angle (Phase 1)

Glioblastoma (Phase 3)

Melanoma (Phase 1)

Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 5